Symbol="IMTX"
AssetType="Common Stock"
Name="Immatics NV"
Description="Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies for the treatment of cancer in the United States. The company is headquartered in Tbingen, Germany."
CIK="1809196"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="PAUL EHRLICH-STRASSE 15, TUBINGEN, DE"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="898590000"
EBITDA="-61604000"
PERatio="None"
PEGRatio="None"
BookValue="2.61"
DividendPerShare="0"
DividendYield="0"
EPS="-1.19"
RevenuePerShareTTM="1.128"
ProfitMargin="-0.852"
OperatingMarginTTM="-0.815"
ReturnOnAssetsTTM="-0.123"
ReturnOnEquityTTM="-0.43"
RevenueTTM="79720000"
GrossProfitTTM="172831000"
DilutedEPSTTM="-1.19"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.905"
AnalystTargetPrice="18.07"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="4.703"
PriceToBookRatio="6.18"
EVToRevenue="2.833"
EVToEBITDA="9.92"
Beta="0.5"
num_52WeekHigh="13.6"
num_52WeekLow="5.9"
num_50DayMovingAverage="10.27"
num_200DayMovingAverage="9.33"
SharesOutstanding="76672000"
DividendDate="None"
ExDividendDate="None"
symbol="IMTX"
open="11.77"
high="11.92"
low="11.03"
price="11.54"
volume="325422.00"
latest_trading_day="2023-07-07"
previous_close="11.72"
change="-0.18"
change_percent="-1.5358%"
aroon_positive_momentum_days="46"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="46"
Volume_recent_avg="406287"
Change_recent_avg="0.01"
Delta_recent_avg="0.52"
Variance_recent_avg="0.26"
Change_ratio_recent_avg="-0.12"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="46"
Aroon_momentum_negative="54"
image_negative_thumbnail_id_1="122"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0054.jpeg"
image_negative_thumbnail_id_2="520"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0085.jpeg"
image_neutral_thumbnail_id_1="558"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0041.jpeg"
image_neutral_thumbnail_id_2="522"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0077.jpeg"
image_positive_thumbnail_id_1="623"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0085.jpeg"
image_positive_thumbnail_id_2="989"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0151.jpeg"
image_professor_thumbnail_id_1="1181"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0015.jpeg"
image_professor_thumbnail_id_2="1175"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0009.jpeg"
